| Literature DB >> 29879879 |
Predrag Sikiric1, Rudolf Rucman1, Branko Turkovic1, Marko Sever1, Robert Klicek1, Bozo Radic1, Domagoj Drmic1, Mirjana Stupnisek1, Marija Misic1, Lovorka Batelja Vuletic1, Katarina Horvat Pavlov1, Ivan Barisic1, Antonio Kokot1, Marina Peklic1, Sanja Strbe1, Alenka Boban Blagaic1, Ante Tvrdeic1, Dinko Stancic Rokotov1, Hrvoje Vrcic1, Mario Staresinic1, Sven Seiwerth1.
Abstract
Years ago, we revealed a novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157, particular anti-ulcer peptide that heals different organs lesions when given as a therapy, native in human gastric juice while maintaining GI-tract mucosal integrity, already tested in trials (ulcerative colitis and now multiple sclerosis). The stomach cytoprotection is the most fundamental concept, stomach cell protection and endothelium protection are largely elaborated, but so far cell, protection and endothelium protection outside of the stomach were not implemented in the therapy. However, having managed these two points, stomach cell protection and endothelium protection, either one or together, even much more than standard cytoprotective agents do, BPC 157 employed large scale of its beneficial effects seen in various organs. Providing endothelium protection, BPC 157 was shown to prevent formation and reverse established thrombosis in anastomosed abdominal aorta as well as venous thrombosis after inferior caval vein occlusion, and attenuate bleeding prolongation and thrombocytopenia after amputation, without or with anticoagulants, or venous occlusion, and finally counteract effect of L-NAME and/or L- arginine. Now, with BPC 157 application, we reveal the third most important part of the cytoprotection concept: with the stomach cell and endothelium protection to recover mucosal integrity, BPC 157 as prototype cytoprotective agent should also control blood vessel function, depending upon injury, perforated defect or vessel obstruction. After a perforated injury (i.e., stomach), BPC 157 therapy activates blood vessels "running" towards defect. After obstruction (i.e., inferior caval vein), BPC 157 activates vessels "running" towards bypassing defect, collaterals functioning. Reestablished blood flow, and largely reversed injurious course may practically implement the cytoprotection concept. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: Stable gastric pentadecapeptide BPC 157; control of blood vessels function; cytoprotection; endothelium protection; organoprotection; stomach cells protection.
Mesh:
Substances:
Year: 2018 PMID: 29879879 DOI: 10.2174/1381612824666180608101119
Source DB: PubMed Journal: Curr Pharm Des ISSN: 1381-6128 Impact factor: 3.116